ReproCELL Incorporated (4978.T) JPX

162.00

-6(-3.57%)

Updated at November 14 02:27PM

Currency In JPY

ReproCELL Incorporated

Address

MetLife Shin-Yokohama Building

Yokohama, 222-0033

Japan

Phone

81 45 475 3887

Sector

Healthcare

Industry

Biotechnology

Employees

96

First IPO Date

June 26, 2013

Key Executives

NameTitlePayYear Born
Dr. Shuji Yokoyama Ph.D.Chief Executive Officer, President & Representative Director01968
Mr. Ramakrishna V. ModaliChief Executive Officer of REPROCELL USA Ltd & CEO of Bioserve Biotechnologies India0N/A
Dr. David BuntonChief Executive officer of REPROCELL Europe0N/A
Mr. Daisuke UsuiChief Operating Officer & Director01973

Description

ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, and induced neurons; and 3D cell culture; and labware. The company also provides preclinical genomics, stem cell research, drug efficacy, safety, & ADME, human tissue samples, therapeutic pipeline, clinical laboratory services, clinical diagnostic services, and gmp ipsc master cell bank services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.